An immunoglobulin G (IgG)-like bispecific T-cell engaging antibody directed against both natural cytotoxicity triggering receptor 3 ligand 1 (NCR3LG1; B7-H6) and T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. Upon administration, anti-B7-H6/anti-CD3 bispecific antibody BI 765049 targets and binds to both B7-H6 on tumor cells and CD3 on T-cells. This results in the cross-linking of B7-H6-expressing tumor cells and T-cells, redirects cytotoxic T-lymphocytes (CTLs) to B7-H6-expressing tumor cells, which leads to the CTL-mediated cell death of B7-H6-expressing tumor cells. B7-H6, a member of the B7 family of immune modulators, is expressed in a variety of tumor cell types while minimally or not expressed in normal tissues. It is a specific ligand for the natural killer (NK) cell activating receptor NKp30, and may modulate NK cell function in certain cancers.